International Developed Markets Equity



Annual Shareholder Report

Institutional Class HLIDX | October 31, 2024

This annual shareholder report contains important information about the International Developed Markets Equity Fund ("Fund") for the period of November 1, 2023 to October 31, 2024. You can find additional information about the Fund at HardingLoevnerFunds.com. You can also request this information by calling (877) 435-8105 or by sending an e-mail request to hardingloevnerfunds@ntrs.com.

What were the Fund costs for the period?

(based on a hypothetical \$10,000 investment)

Fund (Class)	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
International Developed Markets Equity (Institutional Class)	\$88	0.79%

Management's Discussion of Fund Performance

The International Developed Markets Equity Institutional Class (HLIDX) returned 22.17% (net of fees and expenses) in the 12-month period ended October 31, 2024. The Fund's benchmark, the MSCI World ex US Index increased 23.84% (net of source taxes).

Key Performance Factors

Developed Markets outside the US rose on hopes that monetary policies would loosen as inflationary pressures eased, particularly in the US and Europe. All sectors gained, led by Financials and Industrials. Shares of the fastest-growing companies outperformed overall. The Fund lagged the index due to poor relative returns in Consumer Staples and Materials. It benefited from strong returns in Health Care and Financials as well as the Portfolio's underweights in Consumer Discretionary and Energy.

Sector Analysis

In Consumer Staples, shares of French cosmetics company L'Oréal were hurt by slowing growth in China and US amid tighter consumer spending. Investors also reacted negatively to news that Canadian gas station convenience store operator Couche-Tard was looking to acquire Seven & I Holding (the parent company of 7-Eleven). Japan's Chugai Pharmaceuticals boosted relative returns in Health Care; it saw continued strong sales of its hemophilia treatment Hemlibra.

Geographic Analysis

French computer-aided design (CAD) software developer Dassault Systèmes reported tepid growth compared to peers in the broader software universe. In Financials, shares of Canada-based Manulife rose after strong results in its Asian wealth management and insurance businesses.

Performance


↑ Top Contributors	↓ Top Detractors
Chugai Pharmaceutical	L'Oréal
Manulife	Dassault Systèmes
TSMC	Genmab
Schneider Electric	Couche-Tard
Adyen	Samsung Electronics

The securities shown do not represent all holdings, and it should not be assumed that investment in these securities has been or will be profitable. The following is available upon request: (1) information describing the methodology of the contribution data and (2) a list showing the weight and relative contribution of all holdings during the period. Contribution is the contribution to overall performance over the period.

Fund Performance

The following graph and chart compare the beginning and ending account values for the most recently completed 10 fiscal years of the Fund. It compares a \$100,000 initial investment in the Fund with an investment in (i) an appropriate, broadbased securities market index and (ii) an additional index that reflects the market sectors in which the Fund invests.

Growth of \$100,000 (USD)



Fund — \$138,499

•••• MSCI World ex US Index — \$147,673

— MSCI EAFE Index — \$149,220

Average Annual Total Return (%)

	1 Year	Since Inception
Fund	22.17	16.86
MSCI World ex US Index	23.84	20.50
MSCI EAFE Index	22.97	21.10

Performance data quoted represents past performance; past performance does not guarantee future results. Fund performance is shown net of fees. Benchmark performance is shown net of withholding taxes. Returns are annualized for periods greater than one year.

Visit HardingLoevnerFunds.com for the most recent performance information. The graph and table do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or redemption of Fund shares.



For additional resources and information about the Fund, scan the QR code or visit HardingLoevnerFunds.com.


During Reporting Period

48

Graphical Representation of Holdings

The table and charts below show the investment makeup of the Fund; percentages indicated and graphical representations are based on the Fund's net asset value.

Top Ten Holdings	%
DBS Group Holdings Ltd.	4.2
Chugai Pharmaceutical Co., Ltd.	4.2
Allianz SE, Reg S	3.9
Schneider Electric SE	3.7
Shell plc	3.7
Haleon plc	3.7
Manulife Financial Corp.	3.6
Roche Holding AG, Genusschein	3.5
Banco Bilbao Vizcaya Argentaria SA	3.0
Sony Group Corp.	2.8



Material Fund Changes

There were no material changes to the Fund during the period ended October 31, 2024.

For more comprehensive information, you may review the Fund's next prospectus, which we expect to be available by February 28, 2025 at HardingLoevnerFunds.com or upon special request at (877) 435-8105.

Changes in and Disagreements with Accountants

During the period ended October 31, 2024, there were no changes in or disagreements with the Fund's accountant.

Availability of Additional Information

You can find additional information about the Fund such as the prospectus, financial information, fund holdings and proxy voting information at HardingLoevnerFunds.com. You can also request this information by contacting us at (877) 435-8105.

Householding

In order to reduce expenses, we will deliver a single copy of prospectuses, proxies, financial reports and other communication to shareholders with the same residential address, provided they have the same last name or we reasonably believe them to be members of the same family. Unless we are notified otherwise, we will continue to send recipients only one copy of these materials for as long as they remain a shareholder of the Fund. If you would like to receive individual mailings, please call (877) 435-8105 and we will begin sending you separate copies of these materials within 30 days after receiving your request.

